[Treatment and prevention of haemorrhage with recombinant activated factor VII, not only in hemophilia].
Based on the improved insight into the mechanism of blood coagulation in vivo, recombinant factor VIIa (rFVIIa) has been developed as a pro-haemostatic agent. It has been shown that this treatment is effective in patients with haemophilia and an inhibiting antibody against a coagulation factor. Administration of rFVIIa can be effective in the treatment of bleeding episodes and the prevention of perioperative blood loss in a number of other coagulation disorders as well. Initial clinical studies indicate that administration of rFVIIa may also reduce blood loss in patients with severe bleeding without pre-existent abnormalities in blood coagulation, but this requires confirmation in additional clinical trials.
Levi
M
M
Academisch Medisch Centrum/Universiteit van Amsterdam, afd. Inwendige Geneeskunde, Meibergdreef 9, 1105 AZ Amsterdam. m.m.levi@amc.uva.nl
Friederich
Ph W
PW
van der Meer
J
J
D001323:Autoantibodies / Q000276:immunology; D016063:Blood Loss, Surgical / Q000517:prevention & control; D015942:Factor VIIa / Q000276:immunology / Q000627:therapeutic use*; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy*; D006470:Hemorrhage / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use
D001323:Autoantibodies; D011994:Recombinant Proteins; D015942:Factor VIIa